GeoVax Labs, Inc., a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, announced that members of its executive medical and scientific team will deliver presentations at the upcoming World Vaccine Congress Europe 2025. The congress will be held October 13–16, 2025, at the RAI Amsterdam Convention Centre in Amsterdam, Netherlands.
Mark J. Newman, PhD, GeoVax Chief Scientific Officer, will participate in the Special Populations Workshop during the Pre-Congress Workshops on Monday, October 13. This workshop brings together international experts to address challenges of vaccine development and deployment for vulnerable populations, including the immunocompromised. Dr. Newman's presentation, titled "Vaccine design to address the immunocompromised: T-lymphocyte driven…Balanced immunity - Broader specificity - Increased memory," focuses on specialized vaccine design approaches for populations with compromised immune systems.
Kelly T. McKee, Jr., MD, MPH, GeoVax Chief Medical Officer, will present a scientific poster titled "Interim Safety and Reactogenicity of GEO-CM04S1, an MVA-vectored, multi-antigen COVID-19 vaccine, in adults with hematologic malignancies receiving cellular therapies." The poster highlighting the safety profile of the GEO-CM04S1 COVID-19 vaccine in this important target population will be on display in the Poster Zone, Exhibition Hall from October 14–16.
David Dodd, GeoVax President & CEO, emphasized the significance of this international gathering, stating that World Vaccine Congress Europe is one of the most important international gatherings in vaccine research, development and policy. The company looks forward to highlighting the progress of its multi-antigen GEO-CM04S1 in immunocompromised populations, where the need for more effective vaccine options remains urgent.
The World Vaccine Congress Europe convenes global experts across science, clinical development, manufacturing, and public health. More details about the congress can be found at https://www.terrapinn.com/conference/world-vaccine-congress-europe.
GeoVax's lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials. The vaccine is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom current authorized COVID-19 vaccines are insufficient. It is also being studied as a booster vaccine in patients with chronic lymphocytic leukemia and as a more robust, durable COVID-19 booster among healthy patients who previously received mRNA vaccines.
The presentations at the World Vaccine Congress Europe represent significant progress in addressing the critical need for effective vaccines in immunocompromised populations. These patients often respond poorly to conventional vaccines, leaving them vulnerable to severe COVID-19 outcomes. The interim safety data and specialized vaccine design approaches being presented could have substantial implications for global public health, particularly for the millions of immunocompromised individuals worldwide who remain at elevated risk from COVID-19 despite available vaccination options.
For additional information about GeoVax's clinical programs and corporate updates, visit https://www.geovax.com.
